. Competition binding curves of D2AAK4 in radioligand binding assays at the indicated receptors. Concentration-dependent displacement of the specific radioligand binding by compound D2AAK4 and the corresponding reference compound at the human cloned receptors indicated. The graphs show the data (mean ± SEM) of a representative experiment out of two (or three for 5-HT2A) independent experiments performed in duplicate. pKi (mean ± SEM; n = 3 experiments performed in duplicate) and average Ki (nM) values for reference compounds included as internal controls in the binding assays were: haloperidol (D1) = 8.30 ± 0.07 (5.22 nM); haloperidol (D1) = 7.93 ± 0.02 (11.8 nM); haloperidol (D3) = 8.00 ± 0.08 (10.5 nM); 5-carboxamidotryptamine (5-CT) (5-HT1A) = 9.00± 0.06 (1.04 nM); methysergide (5-HT2A) = 9.29 ± 0.07 (0.53 nM); clozapine (5-HT7) = 6.20 ± 0.05 (632 nM); doxepin (H1) = 9.26 ± 0.18 (0.55 nM); ipratropium (M1) = 9.27 ± 0.03 (0.53 nM). Table S1 . Results summary of the evaluation of compound D2AAK4 in in vitro functional assays at human cloned D2 and 5-HT2A receptors. a efficacy (% inh., % of inhibition of dopamine response) as D2 antagonist in cAMP assays; b efficacy (% inh., % of inhibition of 5-HT response) and potency (pIC50,log IC50; IC50, concentration of the compound eliciting the 50% of maximal compound response) as 5-HT2A antagonist in IP assays. Data are mean ± SEM of 2-3 independent experiments performed in duplicate or triplicate. 12.1 ± 6.0% 44.1 ± 1.5% 97.4 ± 1.6% 6.15 ± 0.14 714
